198 related articles for article (PubMed ID: 20124894)
21. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.
Moreau R; Valla DC; Durand-Zaleski I; Bronowicki JP; Durand F; Chaput JC; Dadamessi I; Silvain C; Bonny C; Oberti F; Gournay J; Lebrec D; Grouin JM; Guémas E; Golly D; Padrazzi B; Tellier Z
Liver Int; 2006 Feb; 26(1):46-54. PubMed ID: 16420509
[TBL] [Abstract][Full Text] [Related]
22. Ascites: diagnosis and management.
Hou W; Sanyal AJ
Med Clin North Am; 2009 Jul; 93(4):801-17, vii. PubMed ID: 19577115
[TBL] [Abstract][Full Text] [Related]
23. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
24. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
25. Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension.
Vlavianos P; Mac Mathuna P; Williams R; Westaby D
Clin Sci (Lond); 1999 May; 96(5):475-81. PubMed ID: 10209079
[TBL] [Abstract][Full Text] [Related]
26. Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial.
Degoricija V; Zjacic-Rotkvic V; Marout J; Sefer S; Troskot B
Croat Med J; 2003 Apr; 44(2):178-86. PubMed ID: 12698509
[TBL] [Abstract][Full Text] [Related]
27. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis.
Wong F; Liu P; Lilly L; Bomzon A; Blendis L
Clin Sci (Lond); 1999 Sep; 97(3):259-67. PubMed ID: 10464050
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis.
Luca A; García-Pagán JC; Bosch J; Feu F; Jiménez W; Ginés A; Fernández M; Escorsell A; Arroyo V; Rodés J
Hepatology; 1995 Sep; 22(3):753-8. PubMed ID: 7657279
[TBL] [Abstract][Full Text] [Related]
29. [Hepatorenal syndrome].
Mijac D; Kezić A; Stojimirović B
Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
[TBL] [Abstract][Full Text] [Related]
30. Clinical indications for the albumin use: still a controversial issue.
Caraceni P; Domenicali M; Tovoli A; Napoli L; Ricci CS; Tufoni M; Bernardi M
Eur J Intern Med; 2013 Dec; 24(8):721-8. PubMed ID: 23790570
[TBL] [Abstract][Full Text] [Related]
31. Drug insight: the role of albumin in the management of chronic liver disease.
Wong F
Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4(1):43-51. PubMed ID: 17203088
[TBL] [Abstract][Full Text] [Related]
32. Fluid resuscitation in patients with cirrhosis and sepsis: A multidisciplinary perspective.
Durand F; Kellum JA; Nadim MK
J Hepatol; 2023 Jul; 79(1):240-246. PubMed ID: 36868480
[TBL] [Abstract][Full Text] [Related]
33. Albumin infusion in liver cirrhotic patients.
Rena NM; Wibawa ID
Acta Med Indones; 2010 Jul; 42(3):162-8. PubMed ID: 20724771
[TBL] [Abstract][Full Text] [Related]
34. The use of albumin in patients with decompensated cirrhosis: the case in favor.
Maor Y
Isr Med Assoc J; 2005 Feb; 7(2):115-8. PubMed ID: 15729966
[TBL] [Abstract][Full Text] [Related]
35. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.
Fernández J; Navasa M; Garcia-Pagan JC; G-Abraldes J; Jiménez W; Bosch J; Arroyo V
J Hepatol; 2004 Sep; 41(3):384-90. PubMed ID: 15336440
[TBL] [Abstract][Full Text] [Related]
36. Review article: volume expansion in patients with cirrhosis.
Henriksen JH; Kiszka-Kanowitz M; Bendtsen F
Aliment Pharmacol Ther; 2002 Dec; 16 Suppl 5():12-23. PubMed ID: 12423449
[TBL] [Abstract][Full Text] [Related]
37. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
38. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
Meltzer J; Brentjens TE
Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
[TBL] [Abstract][Full Text] [Related]
39. Ascites and spontaneous bacterial peritonitis: an Asian perspective.
Lee JM; Han KH; Ahn SH
J Gastroenterol Hepatol; 2009 Sep; 24(9):1494-503. PubMed ID: 19743995
[TBL] [Abstract][Full Text] [Related]
40. Review article: albumin for circulatory support in patients with cirrhosis.
Ginès P; Guevara M; De Las Heras D; Arroyo V
Aliment Pharmacol Ther; 2002 Dec; 16 Suppl 5():24-31. PubMed ID: 12423450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
